Drugs that contain Oxycodone Hydrochloride
1. List of Oxaydo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8409616 | ZYLA | Extended release opioid abuse deterrent compositions and methods of making same |
Nov, 2023
(9 months from now) | |
| US7510726 | ZYLA | Methods and compositions for deterring abuse of opioid containing dosage forms |
Nov, 2023
(9 months from now) | |
| US7981439 | ZYLA | Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof |
Nov, 2023
(9 months from now) | |
| US8637540 | ZYLA | Compositions for deterring abuse of opioid containing dosage forms |
Nov, 2023
(9 months from now) | |
| US9492443 | ZYLA | Abuse deterrent compositions and methods of making same |
May, 2024
(1 year, 3 months from now) | |
| US7201920 | ZYLA | Methods and compositions for deterring abuse of opioid containing dosage forms |
Mar, 2025
(2 years from now) | |
Market Authorisation Date: 17 June, 2011
Treatment: NA
Dosage: TABLET;ORAL
2. List of Oxycontin drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(2 years from now) | |
| US10696684 | PURDUE PHARMA LP | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(2 years from now) | |
| US10407434 | PURDUE PHARMA LP | Process for preparing oxycodone compositions |
Mar, 2025
(2 years from now) | |
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675610 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(4 months from now) | |
| US10369109 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(4 months from now) | |
| US10675278 | PURDUE PHARMA LP | Crush resistant delayed-release dosage forms |
Nov, 2023
(9 months from now) | |
| US8309060 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(9 months from now) | |
| US10130591 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(9 months from now) | |
| US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9775808 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US8894988 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US8808741 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9492392 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9492393 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US8894987 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Mar, 2030
(7 years from now) | |
Market Authorisation Date: 05 April, 2010
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE;ORAL
3. List of Roxybond drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10314788 | PROTEGA PHARMS | Pharmaceutical compositions configured to deter dosage form splitting |
Aug, 2028
(5 years from now) | |
| US7955619 | PROTEGA PHARMS | Abuse resistant drugs, method of use and method of making |
Aug, 2028
(5 years from now) | |
Market Authorisation Date: 20 April, 2017
Treatment: NA
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic